Mirum: Positive Topline Data in Phase 3 in Progressive Familial Intrahepatic Cholestasis

 

• Met primary endpoint (p=0.0098); highly statistically significant effects in all PFIC subtypes.
• Significant improvements in total bilirubin and growth versus placebo at six months.
• Mirum plans to submit these data to regulatory agencies.
• Mirum to host conference call to discuss data today, October 24, at 9:00 a.m. ET/6:00 a.m. PT.

Mirum will be hosting a conference call to discuss the topline data from the MARCH study today, Monday, October 24, 2022, at 9:00 a.m. ET/6:00 a.m. PT. Join the call by dialing 1-646-904-5544 (US) or 1-844-200-6205 (toll-free), call ID: 200410. You may also access the webcast through Mirum’s Investor Relations site.

https://www.biospace.com/article/releases/positive-topline-data-announced-from-mirum-s-livmarli-phase-3-march-study-in-progressive-familial-intrahepatic-cholestasis-pfic-/